Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BUTENAFINE HYDROCHLORIDE vs AMBISOME
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Inhibits squalene epoxidase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
Amphotericin B binds to ergosterol in fungal cell membranes, forming pores that disrupt membrane integrity, leading to leakage of intracellular contents and fungal cell death.
Topical treatment of tinea pedis (athlete's foot), tinea cruris (jock itch), and tinea corporis (ringworm) due to Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum.
Empirical therapy for presumed fungal infection in febrile neutropenic patients,Treatment of cryptococcal meningitis in HIV-infected patients,Treatment of visceral leishmaniasis,Treatment of invasive aspergillosis (alternate therapy),Treatment of candidiasis (invasive and mucosal),Treatment of histoplasmosis (severe disseminated),Treatment of blastomycosis (severe),Treatment of coccidioidomycosis (severe),Treatment of mucormycosis,Treatment of fusariosis,Treatment of talaromycosis (penicilliosis)
1% cream applied topically once daily for 2 weeks for tinea pedis, 1 week for tinea corporis/cruris.
3-5 mg/kg/day intravenously for systemic fungal infections; for visceral leishmaniasis: 3 mg/kg/day IV on days 1-5, 14, and 21.
Terminal elimination half-life is approximately 35–40 hours following topical application; long half-life supports once-daily dosing.
Terminal elimination half-life: approximately 7–10 hours (initial phase), with a prolonged terminal half-life of 100–153 hours due to slow redistribution from tissues; clinically, this supports once-daily dosing after initial accumulation.
Not significantly metabolized; undergoes minimal hepatic metabolism via CYP enzymes (unknown specific isoforms).
Amphotericin B is predominantly cleared via the reticuloendothelial system and is excreted slowly in urine and feces. Metabolism is not well characterized, but it is not extensively metabolized by liver enzymes.
Primarily metabolized in the liver; minimal excretion of unchanged drug. Less than 5% of a topical dose is absorbed systemically; excreted in urine and feces as metabolites.
Renal: negligible (<1% unchanged); Biliary/fecal: primary route, approximately 90% of dose recovered in feces as parent drug and metabolites; Urinary: minimal (less than 1% as unchanged drug).
Approximately 60–70% bound to plasma proteins, predominantly albumin.
Highly bound (>90%), primarily to albumin and alpha-1-acid glycoprotein.
Not well characterized due to minimal systemic absorption; estimated volume of distribution is very low, consistent with extensive tissue binding or limited distribution.
Vd: 0.4–0.6 L/kg; reflects extensive tissue distribution, particularly into organs of the reticuloendothelial system (liver, spleen).
Topical: Systemic bioavailability is less than 5% following topical administration; oral bioavailability has not been established as drug is not used systemically.
Intravenous: 100% (only route of administration).
No dose adjustment required; negligible systemic absorption.
No dose adjustment required for renal impairment; use caution in patients with pre-existing renal disease and monitor renal function.
No dose adjustment required; negligible systemic absorption.
No specific dose adjustment for Child-Pugh class A or B; for Child-Pugh class C, consider dose reduction or increased monitoring due to potential hepatotoxicity.
≥12 years: same as adult; <12 years: safety and efficacy not established; use only if clearly needed.
For systemic fungal infections: 3-5 mg/kg/day IV; for visceral leishmaniasis: 3 mg/kg/day IV on days 1-5, 14, and 21; weight-based dosing with no maximum daily dose specified.
No specific adjustment; same as adult dosing; monitor for skin irritation.
No specific dose adjustment; monitor renal function closely due to age-related decreased GFR and potential nephrotoxicity.
None.
Amphotericin B products should be used primarily for treatment of severe fungal infections in immunocompromised patients where significant toxicity is justified. Amphotericin B is associated with severe nephrotoxicity, especially when used at higher doses or with other nephrotoxic agents. Infusion-related reactions (fever, chills, rigors, hypotension) are common and may be severe.
For external use only.,Avoid contact with eyes, nose, mouth, and other mucous membranes.,Discontinue if irritation or sensitization occurs.,Not recommended for treatment of onychomycosis or scalp infections.
Nephrotoxicity: Monitor renal function closely; avoid concomitant nephrotoxic drugs when possible.,Infusion reactions: Premedication (e.g., acetaminophen, antihistamines, corticosteroids) may reduce severity.,Electrolyte disturbances: Hypokalemia, hypomagnesemia may occur; monitor and replace as needed.,Hepatotoxicity: Monitor liver function tests.,Cardiotoxicity: Rarely associated with arrhythmias; caution in patients with cardiac disease.,Pancreatitis: Has been reported; consider in patients with abdominal pain.
Hypersensitivity to butenafine hydrochloride or any components of the formulation.
Hypersensitivity to amphotericin B or any component of the formulation (unless the condition is life-threatening and amenable only to amphotericin B therapy)
No clinically significant food interactions reported. Butenafine is applied topically and systemic absorption is minimal, so dietary restrictions are not required.
No known significant food interactions. Grapefruit juice does not affect liposomal amphotericin B metabolism.
FDA Pregnancy Category B. No evidence of teratogenicity in animal studies; inadequate human data. Risk cannot be ruled out; avoid use in first trimester unless clearly needed.
Pregnancy Category A. No evidence of teratogenicity in animal studies; no adequate human studies in first trimester. In second and third trimesters, use only if clearly needed; no known fetal risks.
Unknown if excreted in human milk; M/P ratio not established. Use with caution in nursing mothers; consider benefits vs risks.
Excretion in human milk unknown; caution advised. M/P ratio not available.
No dose adjustment required based on pharmacokinetic changes in pregnancy; topical application has minimal systemic absorption.
No dose adjustment required for systemic exposure in pregnancy; pharmacokinetic changes not significant.
Butenafine hydrochloride is a benzylamine antifungal with fungicidal activity against dermatophytes (e.g., Trichophyton rubrum, T. mentagrophytes, Epidermophyton floccosum) and yeasts (Malassezia spp.). It inhibits squalene epoxidase, leading to accumulation of squalene and disruption of fungal cell membrane synthesis. Applied once or twice daily for 1–4 weeks depending on indication. For tinea pedis (athlete's foot), treatment should extend 1 week beyond resolution to prevent recurrence. Avoid occlusion unless directed; may increase irritation. Contraindicated in hypersensitivity to any component. For severe or resistant cases, consider combination with keratolytics (e.g., salicylic acid) to enhance penetration.
Am Bisome (liposomal amphotericin B) is preferred over conventional amphotericin B due to reduced nephrotoxicity and infusion-related reactions. Dose adjustment not required in renal impairment, but monitor renal function closely. Premedication with acetaminophen, diphenhydramine, and hydrocortisone may reduce infusion reactions. For cryptococcal meningitis in HIV, combination with flucytosine is recommended. Not interchangeable with other amphotericin B formulations; verify dose and product before administration.
Apply butenafine cream exactly as prescribed: clean and dry the affected area before application.,Use enough medication to cover the affected skin and a small margin of healthy surrounding skin.,Wash your hands after applying, unless treating the hands.,Do not cover the treated area with bandages or dressings unless instructed by your doctor.,Complete the full course of treatment even if symptoms improve, to prevent recurrence.,Notify your doctor if no improvement after 2–4 weeks or if irritation, redness, or blistering occurs.,Avoid contact with eyes, mouth, nose, or broken skin; if accidental contact occurs, rinse with water.,Do not use for conditions other than those prescribed; butenafine is for external use only.
Take exactly as prescribed; do not skip doses or stop early.,Infusion reactions (fever, chills, nausea) may occur; report these to your healthcare provider.,Drink plenty of fluids unless advised otherwise by your doctor.,Contact your doctor immediately if you experience signs of allergic reaction (rash, itching, swelling, severe dizziness, trouble breathing).,Tell your doctor about all medications you are taking, including over-the-counter drugs and herbal supplements.,This medication can cause kidney problems; you will need regular blood tests.
"Etravirine, a non-nucleoside reverse transcriptase inhibitor (NNRTI), is primarily metabolized by CYP3A4 and CYP2C19. Butenafine, an antifungal agent, is also metabolized by CYP3A4. Concurrent use may inhibit the metabolism of butenafine, leading to increased systemic exposure and potential toxicity, including hepatotoxicity or QT prolongation."
"Ranolazine, an antianginal agent, inhibits CYP3A4 and CYP2D6, reducing the metabolism of Butenafine, an antifungal agent typically metabolized by these enzymes. This results in significantly elevated Butenafine serum concentrations, increasing the risk of systemic adverse effects such as hepatotoxicity and QT prolongation. Co-administration may lead to enhanced antifungal efficacy but also potential toxicity."
"Butenafine, an allylamine antifungal, inhibits squalene epoxidase, a key enzyme in ergosterol biosynthesis, leading to fungal cell death. Bepridil, a calcium channel blocker with class I antiarrhythmic properties, prolongs the QT interval by blocking cardiac potassium channels, increasing the risk of torsades de pointes. When combined, butenafine may further inhibit hERG potassium channels in cardiac myocytes, potentiating QT prolongation and elevating the risk of life-threatening ventricular arrhythmias, particularly in patients with preexisting QT prolongation or electrolyte abnormalities."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BUTENAFINE HYDROCHLORIDE vs AMBISOME, answered by our medical review team.
BUTENAFINE HYDROCHLORIDE is a Antifungal that works by Inhibits squalene epoxidase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.. AMBISOME is a Antifungal that works by Amphotericin B binds to ergosterol in fungal cell membranes, forming pores that disrupt membrane integrity, leading to leakage of intracellular contents and fungal cell death.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BUTENAFINE HYDROCHLORIDE and AMBISOME depend on the specific clinical indication. These are both Antifungal agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BUTENAFINE HYDROCHLORIDE is: 1% cream applied topically once daily for 2 weeks for tinea pedis, 1 week for tinea corporis/cruris.. The standard adult dose of AMBISOME is: 3-5 mg/kg/day intravenously for systemic fungal infections; for visceral leishmaniasis: 3 mg/kg/day IV on days 1-5, 14, and 21.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BUTENAFINE HYDROCHLORIDE and AMBISOME in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BUTENAFINE HYDROCHLORIDE is classified as Category C. FDA Pregnancy Category B. No evidence of teratogenicity in animal studies; inadequate human data. Risk cannot be ruled out; avoid use in first trimester unless clearly needed.. AMBISOME is classified as Category C. Pregnancy Category A. No evidence of teratogenicity in animal studies; no adequate human studies in first trimester. In second and third trimesters, use only if clearly needed; no . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.